摘要
目的 :观察扎鲁司特治疗糖皮质激素抵抗型哮喘的临床效果。方法 :42例糖皮质激素抵抗型哮喘患者口服扎鲁司特 40 mg,每日二次 ,疗程 14d,治疗前后根据临床表现进行症状评分 ,并测量肺功能、最大呼气流速 (PEFR)、1s用力呼气量 (FEV 1)、1s用力呼气容积占肺活量比值 (FEV1/ FVC)等各项指标。结果 :治疗前后 PEFR、FEV 1、FEV1/ FVC及症状评分均显著改善 (P<0 .0 1) ,无明显不良反应。结论
Objective:To observe the efficacy of Zafirlukast in treating steroid resistant asthma.Methods:Forty-two patients with steroid-resistant asthma were treated with afirlukast (40 mg,po,bid) for 2 weeks.Results:The patients’ PEFR, FEV1,FEV1/FVC and symptom scores were improved at the end of this trial( P <0.01).No serious adverse relation was observed.Conclusion:Zafirlukast is a safe and effective drug for steroid-resistant asthma.
出处
《山西临床医药》
2001年第2期105-106,共2页
Shanxi Clinical Medicine
